期刊
CANCER IMMUNOLOGY RESEARCH
卷 3, 期 9, 页码 978-985出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2326-6066.CIR-15-0095
关键词
-
资金
- Ludwig Cancer Research
- Belgian Program on Interuniversity Poles of Attraction
- Belgian State, Prime Minister's Office, Science Policy Programming
- Belgian Cancer Plan [29_049]
- Fonds National pour la Recherche Scientifique (Belgium)
- Fondation contre le Cancer (Belgium)
- Fondation Salus Sanguinis (Belgium)
- Fonds Maisin (Belgium)
Cancer patients mount T-lymphocyte responses against antigens expressed selectively by their malignancy, but these responses often fail to control their disease, because tumors select mechanisms that allow them to resist immune destruction. Among the numerous resistance mechanisms that have been proposed, metabolic inhibition of T cells by tryptophan catabolism deserves particular attention, because of the frequent expression of tryptophan-degrading enzymes in human tumors, and because in vitro and in vivo studies have shown that their enzymatic activity can be readily blocked by pharmaco-logic inhibitors, thereby restoring T-cell-mediated tumor cell killing and paving the way to targeted therapeutic intervention. In view of recent observations, and taking into account the differences between human and mouse data that differ in several aspects, in this Cancer Immunology at the Crossroads article, we discuss the role of the three enzymes that have been proposed to control tryptophan catabolism in tumoral immune resistance: indoleamine 2,3-dioxygenase 1 (IDO1), tryptophan 2,3-dioxygenase (TDO), and indoleamine 2,3-dioxygenase 2 (IDO2). (C) 2015 AACR.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据